Search Results

You are looking at 71 - 80 of 96 items for :

  • "skin cancer" x
Clear All
Full access

Suzanne C. O'Neill, Claudine Isaacs, Calvin Chao, Huei-Ting Tsai, Chunfu Liu, Bola F. Ekezue, Nandini Selvam, Larry G. Kessler, Marc D. Schwartz, Tania Lobo and Arnold L. Potosky

whose GEP testing was performed by Genomic Health. From registry data we obtained age at diagnosis, race/ethnicity, marital status, year of diagnosis, and diagnosis of prior primary cancers other than breast cancer, including nonmelanoma skin cancers

Full access

Richard D. Carvajal, Sharon A. Spencer and William Lydiatt

Bernardino EA Mihm MC . The histogenesis and biologic behavior of primary human malignant melanomas of the skin . Cancer Res 1969 ; 29 : 705 – 727 . 30 Chung AF Woodruff JM Lewis JL Jr . Malignant melanoma of the vulva: a report of 44 cases

Full access

Jennifer L. Schwartz, Sandra L. Wong, Scott A. McLean, James A. Hayman, Christopher D. Lao, Jeffrey H. Kozlow, Kelly M. Malloy, Carol R. Bradford, Marcus L. Frohm, Douglas R. Fullen, Lori Lowe and Christopher K. Bichakjian

Thurnher D Erovic BM . Merkel cell carcinoma: interdisciplinary management of a rare disease . J Skin Cancer 2013 ; 2013 : 189342 . 27. Junor EJ Hole DJ Gillis CR . Management of ovarian cancer: referral to a multidisciplinary team matters

Full access

David Cella, Sarah K. Rosenbloom, Jennifer L. Beaumont, Susan E. Yount, Diane Paul, Debra Hampton, Amy P. Abernethy, Paul B. Jacobsen, Karen Syrjala and Jamie H. Von Roenn

other primary malignancy diagnosed or treated within the previous 5 years, excluding nonmelanoma skin cancer. A total of 533 patients participated in the study, with approximately 50 patients per disease site except for bladder cancer (n = 31). Table 1

Full access

Howard A. Chang, Saro H. Armenian and Thanh H. Dellinger

van de Kerkhof PC . Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients . Transpl Int 2010 ; 23 : 191 – 199 . 11. Chin-Hong PV Kwak EJ . Human papillomavirus in solid organ transplantation . Am

Full access

Ashish Rai, Xuesong Han, Zhiyuan Zheng, K. Robin Yabroff and Ahmedin Jemal

aged ≥18 years who were ever diagnosed with cancer (nonmelanoma skin cancer excluded), had ≥1 physician or clinic visit 1 year prior to the first survey encounter, and had no missing data on all satisfaction measures in the first year of the panel

Full access

Edward Christopher Dee, Vinayak Muralidhar, Santino S. Butler, Zizi Yu, Sybil T. Sha, Brandon A. Mahal, Paul L. Nguyen and Nina N. Sanford

a malignancy of any kind.” Those who reported a diagnosis of nonmelanoma skin cancer were excluded, consistent with other cancer survivorship studies. 28 – 31 We included relevant sociodemographic variables captured via NHIS interview, including

Full access

Anthony A. Matthews, Sharon Peacock Hinton, Susannah Stanway, Alexander R. Lyon, Liam Smeeth, Krishnan Bhaskaran and Jennifer L. Lund

cohort are hereafter referred to as “index date”). Women were excluded if they were diagnosed with any other cancer prior to their index date (excluding nonmelanoma skin cancer). Exposures The main exposure was a diagnosis of breast cancer. Women

Full access

Sarju Ganatra, Sourbha S. Dani, Robert Redd, Kimberly Rieger-Christ, Rushin Patel, Rohan Parikh, Aarti Asnani, Vigyan Bang, Katherine Shreyder, Simarjeet S. Brar, Amitoj Singh, Dhruv S. Kazi, Avirup Guha, Salim S. Hayek, Ana Barac, Krishna S. Gunturu, Corrine Zarwan, Anne C. Mosenthal, Shakeeb A. Yunus, Amudha Kumar, Jaymin M. Patel, Richard D. Patten, David M. Venesy, Sachin P. Shah, Frederic S. Resnic, Anju Nohria and Suzanne J. Baron

. Noninvasive cancers, including nonmelanomatous skin cancer, in-situ carcinoma, or precursor hematologic neoplasms, were not included in the definition of cancer. Patients were determined to have CVD if they had a history of coronary artery disease

Full access

breast cancer, 3 for pancreatic cancer, 2 for renal cancer, 2 for prostate cancer, 2 for soft tissue sarcoma, 2 for lung cancer, 2 for ovarian cancer, 2 for bone metastasis, 2 for brain cancer, and 1 for skin cancer ( Table 1 ). A total of 83% studies